UNS Hyper Debt, page-5

Yes, but that means that a new production line can be fully paid at 6 months.
Orbimeds permission needed, but I would like UNIS to carry the debt to allow current shareholders get dividends and future shareholders pay their fair share of production costs.
USA companies usually pay a small dividend and invest in expansion, relying on share price increase.
Because of the long term secure nature of contracts and drug lifespan each production line is capable of operating as a separate income stream.
Also the very small number of shares (110 MM) means that only $110 MM is required as excess to return $1 per full share or 16.5 cents per CDI
As you can see they are going to have huge income flowing in, and the numbers are starting after only minimal start up production.
the share price will gradually rise, but after they start paying a dividend, it will go orbital.
That is why UNIS is not pushing ( marketing ) Unitract- low margin product with competition ans sales staff needed.
UNIS only sells to PHARMAS products that they want after the PHARMAS approach UNIS, and that means that UNIS PRODUCTS CANNOT BE COPIED OR COUNTERFIETED, and neither can the drugs in them
Patience required.